AI Article Synopsis
- Psoriatic skin lesions linked to anti-TNF agents are noted in medical literature, but their causes and best treatment methods are not well understood.
- Vedolizumab, a new medication aimed at treating inflammatory bowel disease, has shown promise in addressing these skin lesions.
- A patient with ulcerative colitis experienced infliximab-related skin issues, but switching to vedolizumab led to both the resolution of skin lesions and remission of the ulcerative colitis.
Article Abstract
Psoriatic skin lesions associated with anti-tumor necrosis factor (TNF) agents are well-described in the medical literature. However, the etiology and optimal management of this condition remain unclear. Vedolizumab is a novel, gut-specific, anti-integrin agent used for the treatment of inflammatory bowel disease (IBD). We report a case of infliximab-associated psoriasiform lesions in an ulcerative colitis patient. Transition to vedolizumab resulted in resolution of the cutaneous lesions without recurrence and remission of his ulcerative colitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508952 | PMC |
| http://dx.doi.org/10.14309/crj.2015.70 | DOI Listing |
Publication Analysis
Top Keywords
ulcerative colitis
12
infliximab-associated psoriasiform
8
successful treatment
4
treatment ulcerative
4
colitis vedolizumab
4
vedolizumab patient
4
patient infliximab-associated
4
psoriasiform rash
4
rash psoriatic
4
psoriatic skin
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!